SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist ofRev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA)with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.
 
Web: www.rawsgearpharma.com
Email: gear@quality-steroid.com
Skype: +8615711952876
Whatsapp +8615711952876